Health Dictionary Find a Doctor

Acute liver failure

For patient information click here

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Husnain Shaukat, M.D [2], Priyamvada Singh, M.B.B.S. [3], Aditya Govindavarjhulla, M.B.B.S. [4]

Synonyms and keywords: ALF, acute hepatic failure, fulminant hepatic failure, fulminant liver failure, fulminant hepatitis

Overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Husnain Shaukat, M.D [2]

Overview

Acute liver failure is a sudden and severe loss of liver function with evidence of encephalopathy and coagulopathy with elevated prothrombin time (PT) and (INR) in a person without a preexisting liver disease. The effects of acute liver failure are due to the loss of its metabolic, secretory and regulatory effects. This results in the accumulation of toxic substances which causes deleterious effects. The major pathophysiological mechanisms of morbidity and mortality in patients with acute liver failure are cerebral edema, hypoperfusion to the liver, idiosyncratic drug reactions, depletion of glutathione and viral hepatitis. Acute liver failure may be classified on the basis of the time interval between the onset of symptoms and the development of encephalopathy as hyperacute, acute, subacute, fulminant, subfulminant and late-onset. Acetaminophen toxicity is the most common cause of acute liver failure in the developed world and viral hepatitis (most commonly hepatitis A, hepatitis B and hepatitis E) is most common in the developing world. Acute liver failure must be differentiated from other diseases that cause signs and symptoms of jaundice, coagulopathy, and encephalopathy. The further evaluation should include liver function tests (aspartate aminotransferase [AST], alanine aminotransferase [ALT], alkaline phosphatase, gamma-glutamyl transpeptidase [GGT], total and direct bilirubin, albumin) and prothrombin time/INR. The diagnosis of acute liver failure is made in the presence of coagulopathy (international normalized ratio [INR], >1.5), hepatic encephalopathy and illness duration of fewer than 24 weeks. The commonly used prognostic indicators to predict mortality in patients with acute liver failure and to identify patients who are likely to benefit from liver transplantation include kings college criteria (use for liver transplantation) and model for end-stage liver disease (MELD) score (to predict mortality in patients with chronic and acute liver disease). Common symptoms of acute liver failure include anorexia, malaise, pruritis, bleeding tendencies, confusion, disorientation, and stupor. In the initial stages of acute liver failure, the patient may have mild mental status changes such as altered sleep pattern but may become confused or develop coma in the later stages as the disease progresses. Physical examination of acute liver failure is remarkable for hepatomegaly, right upper quadrant abdominal tenderness, ascites and [[encephalopathy. The management of acute liver failure involves resuscitation of the patient with adequate nutrition and optimization of fluid balance, monitoring and treating the complications and providing nutritional support. The patient should be treated in an appropriate setting preferably a center with liver transplantation facility. Infections and sepsis are common occurrences of fulminant liver failure. The high standards of infection control should be practiced to minimize the nosocomial sepsis. In stage 3 and 4 encephalopathy, intubation and mechanical ventilation are indicated. Acetylcysteine is used for acetaminophen poisoning for up to 72 hours after ingestion. Every effort should be made to seek out the specific cause of acute liver failure since specific treatments are available for some causes of acute liver failure. However, inappropriately prolonged investigations may make surgery impossible because of progression of sepsis and multiorgan failure. The candidates for liver transplantation should be identified as quickly as possible because the progression to multiorgan failure results in deterioration in many patients who are awaiting liver transplantation. While many people who develop acute liver failure recover with supportive treatment, liver transplantation is often required in people who continue to deteriorate or have poor prognostic factors. Effective measures for the primary prevention of acute liver failure include vaccination, proper personal hygiene, maintaining proper body weight, taking precautions while handling needles, blood, body piercing, tattooing and sexual practices. Effective measures for secondary prevention of acute liver failure include management of chronic liver disease and its complications.

Historical Perspective

The hepatic and mental disturbance association dates back to Hippocrates. In the sixteenth century, Ballonius was the first to describe hepatic coma. In 1860, Frerichs described the terminal mental changes in patients with cirrhosis and yellow atrophy of the liver. In 1970, Trey and Davidson introduced the term fulminant hepatic failure. Later it was suggested that the term fulminant should be confined to patients who develop jaundice to encephalopathy within 2 weeks. Terms subfulminant hepatic failure and late-onset hepatic failure were coined for onset between 2 weeks to 3 months and for 8 weeks to 24 weeks respectively. The term of acute liver failure was proposed by King’s college group.

Classification

Acute liver failure may be classified on the basis of the time interval between the onset of symptoms and the development of encephalopathy as hyperacute, acute, subacute, fulminant, subfulminant and late-onset. The different classification systems used are O’Grady system, Bernuau system, and Japanese system. This classification based on time duration provides helpful clues about etiology, complications, and prognosis such as in hyperacute cases, the cause is usually viral infections or acetaminophen toxicity. The subacute cases can be due to idiosyncratic drug reactions and can also be confused with chronic liver disease. The hyperacute liver failure has a better prognosis than subacute liver failure.

Pathophysiology

Acute liver failure is a sudden and severe loss of liver function with evidence of encephalopathy and coagulopathy with elevated prothrombin time (PT) and (INR) in a person without a preexisting liver disease. The effects of acute liver failure are due to the loss of its metabolic, secretory and regulatory effects. This results in the accumulation of toxic substances and causes deleterious effects. The major pathophysiological mechanisms of morbidity and mortality in patients with acute liver failure are cerebral edema, hypoperfusion to the liver, idiosyncratic drug reactions, depletion of glutathione and viral hepatitis. Cerebral edema in acute liver failure can be due to vasogenic and cytotoxic effects. In cytotoxic type, there is intracellular swelling and blood-brain barrier is intact. In vasogenic type, the blood-brain barrier breaks down and plasma and water accumulate in the extracellular space. The increased ammonia concentration in liver failure in combination with the glutamine produced by the astrocytes causes excess levels of glutamine with the help of enzyme glutamine synthetase. The excess glutamine is cytotoxic and can disturb the osmotic gradient which can result in brain swelling. In acute liver failure, the increased levels of nitric oxide in the circulation can also disrupt the cerebral autoregulation. Acetaminophen is the leading cause of acute liver failure in the United States. Acetaminophen causes dose-related toxicity. Toxicity is rarely seen at normal therapeutic doses (up to 4 g/day) without underlying liver disease. Viral hepatitis is the leading cause of acute liver failure in the developing world. Hepatitis A, B, D (associated with B), and E (in endemic countries) are commonly associated with acute liver failure.

Causes

The causes of acute liver failure can be categorized into viral, drugs and toxins, vascular and metabolic. Common causes of acute liver failure include acetaminophen toxicity, viral hepatitis (most commonly hepatitis A, hepatitis B and hepatitis E), alcoholic hepatitis, autoimmune, sepsis, right heart failure and idiopathic. Acetaminophen toxicity is the most common cause of acute liver failure in the developed world and viral hepatitis (most commonly hepatitis A, hepatitis B and hepatitis E) is most common in the developing world.

Differentiating Acute liver failure from other Diseases

Acute liver failure must be differentiated from other diseases that cause signs and symptoms of jaundice, coagulopathy, and encephalopathy. The differentials include acute hepatitis, cholestatic jaundice, and hemolytic jaundice. The common causes of acute hepatitis causing acute liver failure include acetaminophen toxicity, viral hepatitis, alcoholic hepatitis, autoimmune hepatitis, acute fatty liver of pregnancy, Wilson’s disease, ischemic hepatitis and hepatic congestion due to right heart failure and Budd–chiari syndrome.

Epidemiology and Demographics

The incidence of acute liver failure in the United States is 2000-2300 cases annually. In the year 2009, the diagnosis of acute hepatic necrosis was 420 cases per 100,000 cases of all adult liver transplants in the United States. In the year 1998 to 2008, according to the United States acute liver failure (ALF) registry statistics, the most common cause of acute liver failure was acetaminophen with 46000 cases per 100,000 individuals and 12000 cases per 100,000 individuals for other drugs. Acute hepatitis B is the cause of acute liver failure in 1000 individuals per 100,000 individuals but it increases to 20,000 individuals per 100,000 individuals with hepatitis D virus co-infection. Acute liver failure is more common in women than men, and women with acute liver failure were older than men. Women are more commonly affected with autoimmune hepatitis and hepatitis E viral infection than men. The acute liver failure is seen more in the white population with 74,000 individuals per 100,000 individuals, 10,000 individuals per 100,000 individuals in the Hispanics, 3000 individuals per 100,000 individuals in the Black population and 5000 individuals per 100,000 individuals in the Asian population. The most common cause of acute liver failure in the developing countries is viral infection mainly hepatitis A and hepatitis B. The most common cause of acute liver failure in the developed world is acetaminophen toxicity. The acute liver failure secondary to hepatitis B is also on the rise in the developed world due to immigration.

Risk Factors

The risk factors in the development of acute liver failure can be categorized into viral, drugs and toxins, vascular, metabolic and systemic illnesses. Common risk factors of acute liver failure include acetaminophen toxicity, viral hepatitis (most commonly hepatitis A, hepatitis B and hepatitis E), alcoholic hepatitis, autoimmune hepatitis, sepsis, heart failure, renal failure, immunocompromised state, older age and malnourishment. Acetaminophen toxicity is the most common risk factor of acute liver failure in the developed world and viral hepatitis (most commonly hepatitis A, hepatitis B and hepatitis E) is most common in the developing world.

Screening

There is insufficient evidence to recommend routine screening for an acute liver failure.

Natural History, Complications and Prognosis

Acute liver failure is a sudden and severe loss of liver function with evidence of encephalopathy and coagulopathy with elevated prothrombin time (PT) and (INR) in a person without the preexisting liver disease. The commonly used time duration for an acute liver disease is < 26 weeks. Acute liver failure can be hyperacute, acute or subacute depending upon how long the patient has signs and symptoms of liver failure. If left untreated, patients with acute liver failure can eventually progress to develop confusion, comatose state, and death. Common complications of acute liver failure are hepatic encephalopathy, cerebral edema, coagulopathy, a systemic inflammatory response syndrome, acute renal failure and acute pulmonary failure. The important factors in determining the prognosis of acute liver failure include patients’ age, the severity of encephalopathy and the underlying cause of acute liver failure. The commonly used prognostic indicators to predict mortality in patients with acute liver failure and to identify patients who are likely to benefit from liver transplantation include kings college criteria ( use for liver transplantation ) and model for end-stage liver disease (MELD) score (to predict mortality in patients with chronic and acute liver disease).

Diagnosis

Acute liver failure is a sudden loss of hepatic function in a patient without any evidence of underlying liver disease. Acute liver failure should be suspected in a patient with mental status changes, jaundice, and right upper quadrant pain or nonspecific symptoms such as malaise, nausea and fatigue of fewer than 26 weeks. The further evaluation should include liver function tests (aspartate aminotransferase [AST], alanine aminotransferase [ALT], alkaline phosphatase, gamma-glutamyl transpeptidase [GGT], total and direct bilirubin, albumin) and prothrombin time/INR. The diagnosis of acute liver failure is made in the presence of coagulopathy (international normalized ratio [INR], >1.5), hepatic encephalopathy and illness duration of fewer than 24 weeks.

Diagnostic Criteria

Acute liver failure is a sudden loss of hepatic function in a patient without any evidence of underlying liver disease. The diagnosis of acute liver failure is made in the presence of coagulopathy (international normalized ratio [INR], >1.5), hepatic encephalopathy and illness duration of fewer than 24 weeks.

History and Symptoms

Obtaining the focused history is an important aspect of making a diagnosis of an acute liver failure. It provides insight into the cause, precipitating factors, prognosis and the correct therapy. Specific areas of focus when obtaining a history from the patient include timing of the onset of jaundice, alcohol intake, medications, family history, risk factors of viral hepatitis and past medical history. Common symptoms of acute liver failure include anorexia, malaise, pruritis, bleeding tendencies, confusion, disorientation, and stupor.

Physical Examination

Patients with acute liver failure may appear lethargic, anorexic and fatigue. In the initial stages of acute liver failure, the patient may have mild mental status changes such as altered sleep pattern but may become confused or develop coma in the later stages as the disease progresses. Physical examination of acute liver failure is remarkable for hepatomegaly, right upper quadrant abdominal tenderness, ascites and encephalopathy.

Laboratory Findings

Acute liver failure can present with nonspecific symptoms and it occurs in healthy individuals without a previous history of liver disease. So, the initial labs in the acute liver failure are planned to evaluate both the etiology and the severity of the disease. All patients with clinical or laboratory evidence of moderate to severe acute hepatitis should have an immediate measurement of prothrombin time and careful evaluation of mental status. If the prothrombin time is prolonged (INR ≥1.5) and there is any evidence of altered sensorium, the diagnosis of acute liver failure should be strongly suspected and hospital admission is mandatory.

Imaging Findings

There are no chest x-ray findings associated with acute liver failure. Computed tomography (CT) scanning can also be done in the workup of acute liver failure especially when the ultrasound is not very sensitive as in case of obese patients and massive ascites. CT scan of the head can be done to exclude other causes of altered mental status such as brain abscess or intracranial mass lesions as well as cerebral edema which is a complication of acute liver failure. Acute liver failure can be accompanied by renal failure. Intravenous contrast used with CT scan can further aggravate renal failure. An ultrasound of the liver can be done in the workup of acute liver failure to evaluate ascites and other causes of hepatic failure. It can also assist in the evaluation of intrahepatic mass, abscess, cirrhosis, and malignancy. A doppler ultrasonography can also evaluate the flow and patency of hepatic vessels (hepatic vein and hepatic artery) to rule out Budd-Chiari syndrome, hepatic congestion, and portal hypertension. In a patient with acute liver failure secondary to hepatic ischemia (elevated transaminases), an echocardiogram can be used to identify the etiology if history, labs and other imaging studies do not identify the cause of hepatic ischemia.

Other Diagnostic Studies

Liver biopsy can be used to identify the definite etiology of acute liver failure. A percutaneous liver biopsy is often contraindicated due to the risk of coagulopathy and overt bleeding. The transjugular liver biopsy is helpful in the workup of acute liver failure if there is a risk of bleeding and findings of biopsy depends on the etiology of the acute liver failure. Liver biopsy can identify the definite cause of acute liver failure such as Wilson disease, autoimmune hepatitis, malignant infiltration or acute fatty liver of pregnancy.

Treatment

Medical Therapy

The management of acute liver failure involves resuscitation of the patient with adequate nutrition and optimization of fluid balance, monitoring and treating the complications and providing nutritional support. The patient should be treated in an appropriate setting preferably a center with liver transplantation facility. Infections and sepsis are common occurrences of fulminant liver failure. The high standards of infection control should be practiced to minimize the nosocomial sepsis. The diagnosis of hepatic injury in hyperacute cases can be a challenge as jaundice can be minimal during that period and confusion or agitation may be the dominant findings. In acute liver failure, the sedative medications should be used with caution as they may mask the worsening encephalopathy and the hepatic clearance may be decreased which can aggravate the sedative effect. However, the short-acting benzodiazepines in low dose can be used during agitation. In acute liver failure patients, opioids are avoided as they decrease the seizure threshold. H2 receptor blockers and proton pump inhibitors are indicated to prevent and treat stress gastropathy. In stage 3 and 4 encephalopathy, intubation and mechanical ventilation are indicated. Acetylcysteine is used for acetaminophen poisoning for up to 72 hours after ingestion. It can dramatically improve the outcome if administered within eight hours of acetaminophen ingestion. The patients with acute liver failure may not have a clear history of acetaminophen intake. Therefore, the threshold for administering acetylcysteine should be low and can also be administered in an acute liver failure of unknown etiology. Every effort should be made to seek out the specific cause of acute liver failure since specific treatments are available for some causes of acute liver failure. However, inappropriately prolonged investigations may make surgery impossible because of progression of sepsis and multiorgan failure.

Surgery

The candidates for liver transplantation should be identified as quickly as possible because the progression to multiorgan failure results in deterioration in many patients who are awaiting liver transplantation. While many people who develop acute liver failure recover with supportive treatment, liver transplantation is often required in people who continue to deteriorate or have poor prognostic factors. The patient’s candidacy for liver transplantation should be assessed based on the patient’s clinical scenario, as well as upon social and financial factors. Patient evaluation for liver transplantation should be done as soon as possible and before encephalopathy occurs. The key common feature among various prognostic evaluation systems is the presence of encephalopathy. Other common features are patient’s age and severity of the liver injury which is assessed by coagulopathy or jaundice. To address the limitations, a wide variety of prognostic systems have been proposed but none has universal acceptance. King’s college criteria is the most well-characterized evaluation system. Common absolute contraindications for liver transplantation include untreated sepsis, uncontrolled extrahepatobillary infection, alcohol abuse, uncontrolled cardiopulmonary disease, cholangiocarcinoma, metastatic malignancy to the liver and life-threatening systemic illness. Common postoperative complications for liver transplantation include infections, graft failure, vascular compromise, biliary stricture or stenosis, anastomosis leakage, thrombosis of hepatic artery and portal vein and depression.

Primary Prevention

Effective measures for the primary prevention of acute liver failure include vaccination, proper personal hygiene, maintaining proper body weight, taking precautions while handling needles, blood, body piercing, tattooing and sexual practices.

Secondary Prevention

Effective measures for secondary prevention of acute liver failure include management of chronic liver disease and its complications. In patients with resolved hepatitis B infection, antiviral prophylaxis can be considered in the patients who have a risk of reactivation such as during increasing levels of immunosuppression.

References

Template:WH Template:WS

Historical Perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Husnain Shaukat, M.D [2]

Overview

The association of hepatic and mental disturbance dates back to Hippocrates. In the sixteenth century, Ballonius was the first to describe hepatic coma. In 1860, Frerichs described the terminal mental changes in patients with cirrhosis and yellow atrophy of the liver. In 1970, Trey and Davidson introduced the term fulminant hepatic failure. Later it was suggested that the term fulminant should be confined to patients who develop jaundice to encephalopathy within 2 weeks. Terms subfulminant hepatic failure and late-onset hepatic failure were coined for onset between 2 weeks to 3 months and for 8 weeks to 24 weeks respectively. The term of acute liver failure was proposed by King’s college group.

Historical Perspective

  • The hepatic and mental disturbance association dates back to Hippocrates ( about 460 – 375 B.C.).[1][2]
  • In the sixteenth century, Ballonius was the first to describe hepatic coma.
  • In 1660, Franciscus Rubeus and in 1725, Jacobus Vercellonius described liver failure further.
  • Wickham Legg wrote a comprehensive review on acute liver atrophy in his book on liver diseases.
  • In 1860, Frerichs described the terminal mental changes in patients with cirrhosis and yellow atrophy of the liver.
  • The concept of inflammatory process was first described by Bright.[1]
  • In 1970, Trey and Davidson introduced the term fulminant hepatic failure.
  • Horaczek’s monograph contained several entities which he called bilious dyscrasia’s. The more severe forms corresponds closely with hepatic coma and anatomically with acute yellow atrophy.
  • Later it was suggested that the term fulminant should be confined to patients who develop jaundice to encephalopathy within 2 weeks. Terms subfulminant hepatic failure and late onset hepatic failure were coined for onset between 2 weeks to 3 months and for 8 weeks to 24 weeks respectively.[3][4]
  • The term of acute liver failure was proposed by Kings college group.[5]

References

  1. 1.0 1.1 Kadam PD, Chuan HH (2016). “Erratum to: Rectocutaneous fistula with transmigration of the suture: a rare delayed complication of vault fixation with the sacrospinous ligament”. Int Urogynecol J. 27 (3): 505. doi:10.1007/s00192-016-2952-5. PMID 26811110.
  2. Trey C, Davidson CS (1970). “The management of fulminant hepatic failure”. Progress in liver diseases. 3: 282–98. PMID 4908702.
  3. Bernuau J, Goudeau A, Poynard T; et al. (1986). “Multivariate analysis of prognostic factors in fulminant hepatitis B”. Hepatology. 6 (4): 648–51. PMID 3732998.
  4. Gimson AE, O’Grady J, Ede RJ, Portmann B, Williams R (1986). “Late onset hepatic failure: clinical, serological and histological features”. Hepatology. 6 (2): 288–94. PMID 3082735.
  5. Sass DA, Shakil AO (2005). “Fulminant hepatic failure”. Liver Transpl. 11 (6): 594–605. doi:10.1002/lt.20435. PMID 15915484.

Template:WH Template:WS

Classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Husnain Shaukat, M.D [2] Aditya Govindavarjhulla, M.B.B.S. [3]

Overview

Acute liver failure may be classified on the basis of the time interval between the onset of symptoms and the development of encephalopathy as hyperacute, acute, subacute, fulminant, subfulminant and late-onset. The different classification systems used are O’Grady system, Bernuau system, and Japanese system. This classification based on time duration provides helpful clues about etiology, complications, and prognosis such as in hyperacute cases, the cause is usually viral infections or acetaminophen toxicity. The subacute cases can be due to idiosyncratic drug reactions and can also be confused with chronic liver disease. The hyperacute liver failure has a better prognosis than subacute liver failure.

Classification

Acute liver failure may be classified on the basis of the duration of the symptoms between the onset of jaundice to the onset of encephalopathy. The different classification systems based on the number of weeks from the appearance of jaundice to the encephalopathy are:[1][2][3][4][5][6]

Classification system Duration
O’Grady System
  • Hyperacute (0 – 1 week)
  • Acute ( From 2nd week – 4 weeks)
  • Subacute ( From 4th week – 12 weeks)
Bernuau System
  • Fulminant ( 0 – 2 weeks)
  • Subfulminant ( 2 weeks – 12 weeks)
Japanese System
  • Fulminant (0 – 8 weeks)
    • Acute ( 0 – 1.5 weeks)
    • Subacute ( 1.5 weeks – 8 weeks)
  • Late-Onset ( 8 weeks – 12 weeks)

Classification based on etiology

There is no established classification of acute liver failure on the basis of etiology. However, it can be classified on the basis of etiology as:[7][8]

Viral

Metabolic

Vascular

Drugs and Toxins

Other

References

  1. O’Grady JG, Schalm SW, Williams R. Acute liver failure: redefining the syndromes. Lancet 1993;342:273-5. PMID 8101303.
  2. O’Grady JG (2005). “Acute liver failure”. Postgraduate medical journal. 81 (953): 148–54. doi:10.1136/pgmj.2004.026005. PMID 15749789.
  3. Williams R (1996). “Classification, etiology, and considerations of outcome in acute liver failure”. Semin Liver Dis. 16 (4): 343–8. doi:10.1055/s-2007-1007247. PMID 9027947.
  4. O’Grady JG, Schalm SW, Williams R (1993). “Acute liver failure: redefining the syndromes”. Lancet. 342 (8866): 273–5. PMID 8101303.
  5. Bernuau J, Rueff B, Benhamou JP (1986). “Fulminant and subfulminant liver failure: definitions and causes”. Semin Liver Dis. 6 (2): 97–106. doi:10.1055/s-2008-1040593. PMID 3529410.
  6. Mochida S, Nakayama N, Matsui A, Nagoshi S, Fujiwara K (2008). “Re-evaluation of the Guideline published by the Acute Liver Failure Study Group of Japan in 1996 to determine the indications of liver transplantation in patients with fulminant hepatitis”. Hepatol Res. 38 (10): 970–9. doi:10.1111/j.1872-034X.2008.00368.x. PMID 18462374.
  7. Lee WM, Squires RH, Nyberg SL, Doo E, Hoofnagle JH (2008). “Acute liver failure: Summary of a workshop”. Hepatology. 47 (4): 1401–15. doi:10.1002/hep.22177. PMC 3381946. PMID 18318440.
  8. Lee WM (2008). “Etiologies of acute liver failure”. Semin. Liver Dis. 28 (2): 142–52. doi:10.1055/s-2008-1073114. PMID 18452114.

Template:WH Template:WS

Pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [2] Associate Editor(s)-in-Chief: Aditya Govindavarjhulla, M.B.B.S. [3] Husnain Shaukat, M.D [4]

Overview

Acute liver failure is a sudden and severe loss of liver function with evidence of encephalopathy and coagulopathy with elevated prothrombin time (PT) and (INR) in a person without a preexisting liver disease. The consequences of acute liver failure are due to the loss of its metabolic, secretory and regulatory effects. This results in the accumulation of toxic substances and causes deleterious effects. The major pathophysiological mechanisms of morbidity and mortality in patients with acute liver failure are cerebral edema, hypoperfusion to the liver, idiosyncratic drug reactions, depletion of glutathione and viral hepatitis. Cerebral edema in acute liver failure can be due to vasogenic and cytotoxic effects. In cytotoxic type, there is intracellular swelling but blood-brain barrier is intact. In vasogenic type, the blood-brain barrier breaks down and plasma and water accumulate in the extracellular space. The increased ammonia concentration in liver failure in combination with the glutamine produced by the astrocytes causes excess levels of glutamine with the help of enzyme glutamine synthetase. The excess glutamine is cytotoxic and may influence the osmotic gradient which could result in brain edema. In acute liver failure, the increased levels of nitric oxide in the circulation can also disrupt the cerebral autoregulation. Acetaminophen is the leading cause of acute liver failure in the United States. Acetaminophen causes dose-related toxicity. Toxicity is rarely seen at normal therapeutic doses (up to 4 g/day) without underlying liver disease. Viral hepatitis is the leading cause of acute liver failure in the developing world. Hepatitis A, B, D (associated with B), and E (in endemic countries) are commonly associated with acute liver failure.

Pathophysiology

Acute liver failure is a sudden and severe loss of liver function with evidence of encephalopathy and coagulopathy with elevated prothrombin time (PT) and (INR) in a person without preexisting liver disease.

Specific Conditions

Acetaminophen Toxicity

Other Drugs

Mushroom Poisoning

Viral Hepatitis

Autoimmune Hepatitis

Ischemic Injury

  • This condition is called shock liver. It is a common occurrence in the ICU with a prevalence of 10%.[4]
  • Shock liver results from severe hypotension due to any causes such as heart failure or vasoconstictive drugs.
  • Early recovery frequently occurs, but the long term outcome depends on the underlying cause of the ischemia.

HELLP Syndrome

Malignancy

Gross Pathology

On gross pathology, characteristic findings of acute liver failure include:

Microscopic Pathology

On microscopic pathology, characteristic findings of acute liver failure include:[6]


Drug induced hepatitis
Soource:By Nephron (Own work) [CC BY-SA 3.0 (https://creativecommons.org/licenses/by-sa/3.0) or GFDL (http://www.gnu.org/copyleft/fdl.html)], via Wikimedia Commons

{{#ev:youtube|G5G9AnVhqhI}}

{{#ev:youtube|l4m3f2KCxLM}}

References

  1. 1.0 1.1 Ostapowicz G, Fontana RJ, Schiødt FV, Larson A, Davern TJ, Han SH, McCashland TM, Shakil AO, Hay JE, Hynan L, Crippin JS, Blei AT, Samuel G, Reisch J, Lee WM (2002). “Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States”. Annals of Internal Medicine. 137 (12): 947–54. PMID 12484709. Retrieved 2012-10-27. Unknown parameter |month= ignored (help)
  2. Catalina MV, Núñez O, Ponferrada A, Menchén L, Matilla A, Clemente G, Bañares R (2003). “[Liver failure due to mushroom poisoning: clinical course and new treatment perspectives]”. Gastroenterología Y Hepatología (in Spanish; Castilian). 26 (7): 417–20. PMID 12887855. Retrieved 2012-10-27.
  3. 3.0 3.1 Schiødt FV, Davern TJ, Shakil AO, McGuire B, Samuel G, Lee WM (2003). “Viral hepatitis-related acute liver failure”. The American Journal of Gastroenterology. 98 (2): 448–53. doi:10.1111/j.1572-0241.2003.t01-1-07223.x. PMID 12591067. Retrieved 2012-10-27. Unknown parameter |month= ignored (help)
  4. Fuhrmann V, Jäger B, Zubkova A, Drolz A (2010). “Hypoxic hepatitis – epidemiology, pathophysiology and clinical management”. Wiener Klinische Wochenschrift. 122 (5–6): 129–39. doi:10.1007/s00508-010-1357-6. PMID 20361374. Retrieved 2012-10-27. Unknown parameter |month= ignored (help)
  5. Woolf GM, Petrovic LM, Rojter SE, Villamil FG, Makowka L, Podesta LG, Sher LS, Memsic L, Vierling JM (1994). “Acute liver failure due to lymphoma. A diagnostic concern when considering liver transplantation”. Digestive Diseases and Sciences. 39 (6): 1351–8. PMID 8200270. Unknown parameter |month= ignored (help); |access-date= requires |url= (help)
  6. [1]

Template:WH Template:WS

Causes

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Husnain Shaukat, M.D [2]

Overview

The causes of acute liver failure can be categorized into viral, drugs and toxins, vascular, and metabolic. Common causes of acute liver failure include acetaminophen toxicity, viral hepatitis (most commonly hepatitis A, hepatitis B and hepatitis E), alcoholic hepatitis, autoimmune, sepsis, right heart failure, and idiopathic. Acetaminophen toxicity is the most common cause of acute liver failure in the developed world and viral hepatitis (most commonly hepatitis A, hepatitis B and hepatitis E) is most common in the developing world.

Causes

Common Causes

The common causes of acute liver failure are:[1][2][3][4][2][5]

Causes by Organ System

Cardiovascular Cardiomyopathy, Congestive heart failure, Heart surgery, Hypoplastic left heart syndrome, Hypotension, Myocarditis, Shock
Chemical / poisoning 8-Hyydroxyquinoline, Amanita phalloides, Amatoxins, Carbon tetrachloride, Ethanol, Gold, Gyromitrin, Iron compounds, Mushroom poisoning, Senecio, Toluene, Yellow phosphorous, Bacillus cereus , Cyanobacteria
Dermatologic No underlying causes
Drug Side Effect Abacavir, Acetaminophen, Acetaminophen and Oxycodone, Albendazole, Allopurinol, Amiodarone, Amitriptyline, Ampicillin, Amoxicillin-clavulanate, Anticonvulsants, Antituberculosis drugs, Aspirin, Atorvastatin, Bromfenac , Carbamazepine, Chaparral, Chelidonium, Ciprofloxacin, Comfrey, Cyclophosphamide, Dantrolene, Dapsone, diclofenac (patch), Didanosine, Dideoxyinosine, Disulfiram, Doxycycline, Efavirenz, Ephedra, Erlotinib, Erythromycin, Etodolac, Fluoroquinolones, Flutamide, Gemtuzumab, Gemtuzumab, Germander tea, Ginseng, Halothane, He Shou Wu, Hydroxychloroquine, Imipramine, Interferon beta, Isoflurane, Isoniazid, Ixabepilone, Kava kava, Ketoconazole, Labetalol, Leflunomide, Loratadine, Lovastatin, Ma Huang, MAO inhibitors, Meloxicam, Methotrexate, Methyldopa, Moxifloxacin, Niacin, Nevirapine, Nicotinic acid, Nitisinone, Nitrofurantoin, Nortriptyline, NSAIDs, Oral contraceptive pills , Pazopanib, Pemoline, Pennyroyal, Phenytoin, Propylthiouracil, Pyrazinamide, Regorafenib, Rifampin, Simvastatin, Skull cap, Statins, Sulfacetamide, Sulfasalazine, Suloctidil, Terbinafine, Tetracycline, Teucrium polium, Tolcapone, Tricyclic antidepressants, Troglitazone, Valproic acid, Ecstacy, Cocaine, Reye’s syndrome
Ear Nose Throat No underlying causes
Endocrine No underlying causes
Environmental No underlying causes
Gastroenterologic Budd-Chiari syndrome, Cirrhosis, Hepatic arterial thrombosis, Hepatic veno-occlusive disease, Ischemic hepatitis, Portal vein thrombosis, Alpha1-antitrypsin deficiency, Acute fatty liver of pregnancy, Liver tumor, Autoimmune hepatitis
Genetic Alpha1-antitrypsin deficiency, Carnitine palmitoyltransferase 1 deficiency, Fructose intolerance, Galactosemia, Hemochromatosis, LCAT deficiency, Sickle cell disease, Tyrosinemia, Wilson’s disease, HELLP syndrome
Hematologic Hemosiderosis, Hemochromatosis, Sickle cell disease, HELLP syndrome, Leukemia
Iatrogenic Extracorporeal membrane oxygenation, Hepatectomy, Reye’s syndrome
Infectious Disease Adenovirus, Bacillus cereus , Cyanobacteria, Cytomegalovirus, Echovirus, Epstein-Barr virus, Fasciola hepatica, Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D, Herpes simplex, Leptospirosis, Non A non B hepatitis , Parainfluenza viruses, Parvovirus, Sepsis, Viral hemorrhagic fever, Viral hepatitis, Visceral leishmaniasis
Musculoskeletal / Ortho Adult onset Still’s disease
Neurologic No underlying causes
Nutritional / Metabolic Fatty acid oxidation pathway diseases, Hemochromatosis, Carnitine palmitoyltransferase 1 deficiency, Fructose intolerance, Galactosemia, LCAT deficiency, Tyrosinemia, Wilson’s disease
Obstetric/Gynecologic Acute fatty liver of pregnancy, HELLP syndrome
Oncologic Leukemia, Liver tumor
Opthalmologic No underlying causes
Overdose / Toxicity Abacavir, Acetaminophen, Allopurinol, Amiodarone, Amitriptyline, Ampicillin, Amoxicillin-clavulanate, Anticonvulsants, Antituberculosis drugs, Aspirin, Atorvastatin, Bromfenac , Carbamazepine, Chaparral, Chelidonium, Ciprofloxacin, Comfrey, Cyclophosphamide, Dantrolene, Dapsone, Didanosine, Dideoxyinosine, Disulfiram, Doxycycline, Efavirenz, Ephedra, Erlotinib, Erythromycin, Etodolac, Fluoroquinolones, Flutamide, Gemtuzumab, Gemtuzumab, Germander tea, Ginseng, Halothane, He Shou Wu, Imipramine, Interferon beta, Isoflurane, Isoniazid, Kava kava, Ketoconazole, Labetalol, Leflunomide, Lovastatin, Ma Huang, MAO inhibitors, Methotrexate, Methyldopa, Moxifloxacin, Nevirapine, Nicotinic acid, Nitisinone, Nitrofurantoin, Nortriptyline, NSAIDs, Oral contraceptive pills , Pazopanib, Pemoline, Pennyroyal, Phenytoin, Propylthiouracil, Pyrazinamide, Regorafenib, Rifampin, Simvastatin, Skull cap, Statins, Sulfasalazine, Suloctidil, Terbinafine, Tetracycline, Teucrium polium, Tolcapone, Tricyclic antidepressants, Troglitazone, Valproic acid, Ecstacy, Cocaine
Psychiatric No underlying causes
Pulmonary Asphyxia, Alpha1-antitrypsin deficiency
Renal / Electrolyte No underlying causes
Rheum / Immune / Allergy Autoimmune hepatitis, Graft versus host disease
Sexual No underlying causes
Trauma No underlying causes
Urologic No underlying causes
Dental No underlying causes
Miscellaneous Alcohol, Cocaine, Cryptogenic, Ecstacy, Heat stroke, Hyperthermia, Hypothermia

Causes in Alphabetical Order

References

  1. Ichai P, Samuel D (2008). “Etiology and prognosis of fulminant hepatitis in adults”. Liver Transpl. 14 Suppl 2: S67–79. doi:10.1002/lt.21612. PMID 18825677.
  2. 2.0 2.1 Ostapowicz G, Fontana RJ, Schiødt FV, Larson A, Davern TJ, Han SH, McCashland TM, Shakil AO, Hay JE, Hynan L, Crippin JS, Blei AT, Samuel G, Reisch J, Lee WM (2002). “Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States”. Ann. Intern. Med. 137 (12): 947–54. PMID 12484709.
  3. Hoofnagle JH, Nelson KE, Purcell RH (2012). “Hepatitis E.” N Engl J Med. 367 (13): 1237–44. doi:10.1056/NEJMra1204512. PMID 23013075.
  4. Wasley A, Fiore A, Bell BP (2006). “Hepatitis A in the era of vaccination”. Epidemiol Rev. 28: 101–11. doi:10.1093/epirev/mxj012. PMID 16775039.
  5. Björnsson E, Olsson R (2005). “Outcome and prognostic markers in severe drug-induced liver disease”. Hepatology. 42 (2): 481–9. doi:10.1002/hep.20800. PMID 16025496.

Template:WH Template:WS

Differentiating Acute Liver Failure from other Diseases

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Husnain Shaukat, M.D [2]

Overview

Acute liver failure must be differentiated from other diseases that cause signs and symptoms of jaundice, coagulopathy, and encephalopathy. The differentials include acute hepatitis, cholestatic jaundice, and hemolytic jaundice. The common causes of acute hepatitis causing acute liver failure include acetaminophen toxicity, viral hepatitis, alcoholic hepatitis, autoimmune hepatitis, acute fatty liver of pregnancy, Wilson’s disease, ischemic hepatitis and hepatic congestion due to right heart failure and Budd–chiari syndrome.

Differentiating Acute Liver Failure from other Diseases

Acute liver failure must be differentiated from other diseases that cause signs and symptoms of jaundice, coagulopathy, and encephalopathy.[1][2][3][4]

Condition Differentiating signs and symtoms Differentiating Tests
Acute hepatits
  • Severe acute hepatitis is followed very closely as it has a potential to develop into acute or subacute hepatic failure.
  • Hepatic encephalopathy is absent.
  • Grades of hepatic encephalopathy are:
    • Grade 1: Trivial lack of awareness; euphoria or anxiety; shortened attention span.
    • Grade 2: Lethargy or apathy; minimal disorientation for time or place; subtle personality change; inappropriate behavior; impaired performance of subtraction.
    • Grade 3:  Somnolence to semi-stupor, but responsive to verbal stimuli; confusion; gross disorientation.
    • Grade 4:  Coma (unresponsive to verbal or noxious stimuli).
Cholestasis
Hemolysis

Abbreviations: RUQ= Right upper quadrant of the abdomen, LFT= Liver function test, SIRS= Systemic inflammatory response syndrome, ERCP= Endoscopic retrograde cholangiopancreatography, N= Normal, AMA= Anti mitochondrial antibodies, LDH= Lactate dehydrogenase, GI= Gastrointestinal, CT= Computed tomography

Classification of jaundice based on etiology Disease History and clinical manifestations Diagnosis
Lab Findings Other blood tests Other diagnostic
Family history Fever RUQ Pain Pruritis AST ALT ALK BLR Indirect BLR Direct Viral serology
Jaundice Hepatocellular Jaundice Hemochromatosis + -/+ ↑/N ↑/N N Ferritin ↑ Liver biopsy
Wilson’s disease + -/+ N ↑/N N Serum cerulloplasmin ↑ Liver biopsy
Viral hepatitis -/+ ↑↑ N ↑/N N + Specific viral antibody for each type
Alcoholic hepatitis ↑↑ N ↑/N N
Drug induced hepatitis -/+ N ↑/N N
Autoimmune hepatitis -/+ -/+ N ↑/N N Anti-LKM antibody Liver biopsy
Cholestatic Jaundice Common bile duct stone -/+ + + N N N Dilated ducts on sono CT/ERCP
Hepatitis A cholestatic type -/+ + + N N N + HAV- AB Abdominal ultrasound
EBV / CMV hepatitis -/+ + + N N N + Positive serology
Primary biliary cirrhosis -/+ -/+ + N/↑ N/↑ ↑? AMA positive Liver biopsy
Primary sclerosing cholangitis -/+ -/+ + N/↑ N/↑ ↑? Beading on MRCP Liver biopsy
Isolated Jaundice Crigler-Najjar type 2 + N N N N Genetic testing
Gilbert + N N N N Genetic testing
Rotor syndrome + N N N N Genetic testing Liver biopsy
Dubin-Johnson syndrome + N N N N Genetic testing Liver biopsy
Hereditory spherocytosis + -/+ N N N N Genetic testing Osmotic fragility
G6PD deficiency + N N N N Genetic testing
Thalassemia + N N N N Genetic testing
Sickle cell disease + N N N N Genetic testing
Paroxismal nocturnal hemoglobinoria N N N N Flocytometery
Immune hemolysis -/+ N N N N Autoantibodies
Hematoma -/+ N N N N Anemia Truma or surgery in history

References

  1. Escorsell A, Mas A, de la Mata M, Spanish Group for the Study of Acute Liver Failure (2007). “Acute liver failure in Spain: analysis of 267 cases”. Liver Transpl. 13 (10): 1389–95. doi:10.1002/lt.21119. PMID 17370334.
  2. Bower WA, Johns M, Margolis HS, Williams IT, Bell BP (2007). “Population-based surveillance for acute liver failure”. Am J Gastroenterol. 102 (11): 2459–63. doi:10.1111/j.1572-0241.2007.01388.x. PMID 17608778.
  3. Kumar R, Shalimar. Bhatia V, Khanal S, Sreenivas V, Gupta SD; et al. (2010). “Antituberculosis therapy-induced acute liver failure: magnitude, profile, prognosis, and predictors of outcome”. Hepatology. 51 (5): 1665–74. doi:10.1002/hep.23534. PMID 20196116.
  4. Lee WM, Stravitz RT, Larson AM (2012). “Introduction to the revised American Association for the Study of Liver Diseases Position Paper on acute liver failure 2011”. Hepatology. 55 (3): 965–7. doi:10.1002/hep.25551. PMC 3378702. PMID 22213561.

Template:WH Template:WS

Epidemiology and Demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Husnain Shaukat, M.D [2]

Overview

The incidence of acute liver failure in the United States is 2000-2300 cases annually. In the year 2009, the diagnosis of acute hepatic necrosis was 420 cases per 100,000 cases of all adult liver transplants in the United States. In the year 1998 to 2008, according to the United States acute liver failure (ALF) registry statistics, the most common cause of acute liver failure was acetaminophen with 46000 cases per 100,000 individuals and 12000 cases per 100,000 individuals for other drugs. Acute hepatitis B is the cause of acute liver failure in 1000 individuals per 100,000 individuals but it increases to 20,000 individuals per 100,000 individuals with hepatitis D virus co-infection. Acute liver failure is more common in women than men, and women with acute liver failure were older than men. Women are more commonly affected with autoimmune hepatitis and hepatitis E viral infection than men. The acute liver failure is seen more in the white population with 74,000 individuals per 100,000 individuals, 10,000 individuals per 100,000 individuals in the Hispanics, 3000 individuals per 100,000 individuals in the Black population and 5000 individuals per 100,000 individuals in the Asian population. The most common cause of acute liver failure in the developing countries is viral infection mainly hepatitis A and hepatitis B. The most common cause of acute liver failure in the developed world is acetaminophen toxicity. The acute liver failure secondary to hepatitis B is also on the rise in the developed world due to immigration.

Epidemiology and Demographics

  • The incidence of acute liver failure in the United States is 2000-2300 cases annually.[1]
  • In the year 2009, the diagnosis of acute hepatic necrosis was 420 cases per 100,000 cases of all adult liver transplants in the United States.[2]
  • In the year 1998 to 2008, according to the United States acute liver failure (ALF) registry statistics, the most common cause of acute liver failure was acetaminophen with 46000 cases per 100,000 individuals and 12000 cases per 100,000 individuals for other drugs.[3]
  • Acute hepatitis B is the cause of acute liver failure in 1000 individuals per 100,000 individuals but it increases to 20,000 individuals per 100,000 individuals with hepatitis D virus co-infection.[4]

Gender

  • Women are more commonly affected with autoimmune hepatitis and hepatitis E viral infection than men.[5]
  • Acute liver failure is more common in women than men and women with acute liver failure were older than men.

Race

  • The acute liver failure is seen more in the white population with 74,000 individuals per 100,000 individuals, 10,000 individuals per 100,000 individuals in the Hispanics, 3000 individuals per 100,000 individuals in the Black population and 5000 individuals per 100,000 individuals in the Asian population.[5][6]

Developed Countries

  • The most common cause of acute liver failure in the developed world is acetaminophen toxicity.[5]
  • The acute liver failure secondary to hepatits B is also on the rise in the developed world due to immigration.

Developing Countries

References

  1. Ichai P, Samuel D (2008). “Etiology and prognosis of fulminant hepatitis in adults”. Liver Transpl. 14 Suppl 2: S67–79. doi:10.1002/lt.21612. PMID 18825677.
  2. McDowell Torres D, Stevens RD, Gurakar A (2010). “Acute liver failure: a management challenge for the practicing gastroenterologist”. Gastroenterol Hepatol (N Y). 6 (7): 444–50. PMC 2933761. PMID 20827368.
  3. Stravitz RT, Kramer DJ (2009). “Management of acute liver failure”. Nat Rev Gastroenterol Hepatol. 6 (9): 542–53. doi:10.1038/nrgastro.2009.127. PMID 19652652.
  4. Shukla NB, Poles MA (2004). “Hepatitis B virus infection: co-infection with hepatitis C virus, hepatitis D virus, and human immunodeficiency virus”. Clin Liver Dis. 8 (2): 445–60, viii. PMID 15481349.
  5. 5.0 5.1 5.2 5.3 Wang FS, Fan JG, Zhang Z, Gao B, Wang HY (2014). “The global burden of liver disease: the major impact of China”. Hepatology. 60 (6): 2099–108. doi:10.1002/hep.27406. PMC 4867229. PMID 25164003.
  6. Larson AM, Polson J, Fontana RJ, Davern TJ, Lalani E, Hynan LS; et al. (2005). “Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study”. Hepatology. 42 (6): 1364–72. doi:10.1002/hep.20948. PMID 16317692.
Risk Factors

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Husnain Shaukat, M.D [2]

Overview

The risk factors in the development of acute liver failure can be categorized into viral, drugs and toxins, vascular, metabolic and systemic illnesses. Common risk factors of acute liver failure include acetaminophen toxicity, viral hepatitis (most commonly hepatitis A, hepatitis B and hepatitis E), alcoholic hepatitis, autoimmune hepatitis, sepsis, heart failure, renal failure, immunocompromised state, older age and malnourishment. Acetaminophen toxicity is the most common risk factor of acute liver failure in the developed world and viral hepatitis (most commonly hepatitis A, hepatitis B and hepatitis E) is most common in the developing world.

Risk Factors

Risk factors in the development of acute liver failure include:[1][2][3][4][2][5]

References

  1. Ichai P, Samuel D (2008). “Etiology and prognosis of fulminant hepatitis in adults”. Liver Transpl. 14 Suppl 2: S67–79. doi:10.1002/lt.21612. PMID 18825677.
  2. 2.0 2.1 Ostapowicz G, Fontana RJ, Schiødt FV, Larson A, Davern TJ, Han SH, McCashland TM, Shakil AO, Hay JE, Hynan L, Crippin JS, Blei AT, Samuel G, Reisch J, Lee WM (2002). “Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States”. Ann. Intern. Med. 137 (12): 947–54. PMID 12484709.
  3. Hoofnagle JH, Nelson KE, Purcell RH (2012). “Hepatitis E.” N Engl J Med. 367 (13): 1237–44. doi:10.1056/NEJMra1204512. PMID 23013075.
  4. Wasley A, Fiore A, Bell BP (2006). “Hepatitis A in the era of vaccination”. Epidemiol Rev. 28: 101–11. doi:10.1093/epirev/mxj012. PMID 16775039.
  5. Björnsson E, Olsson R (2005). “Outcome and prognostic markers in severe drug-induced liver disease”. Hepatology. 42 (2): 481–9. doi:10.1002/hep.20800. PMID 16025496.

Template:WH Template:WS

Screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Husnain Shaukat, M.D [2]

Overview

There is insufficient evidence to recommend routine screening for an acute liver failure.

Screening

There is insufficient evidence to recommend routine screening for an acute liver failure.

References

Template:WS Template:WH

Natural History, Complications and Prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Husnain Shaukat, M.D [2]

Overview

Acute liver failure is a sudden and severe loss of liver function with evidence of encephalopathy and coagulopathy with elevated prothrombin time (PT) and (INR) in a person without preexisting liver disease. The commonly used time duration for an acute liver disease is < 26 weeks. Acute liver failure can be hyperacute, acute or subacute depending upon how long the patient has signs and symptoms of liver failure. If left untreated, patients with acute liver failure can eventually progress to develop confusion, comatose state, and death. Common complications of acute liver failure are hepatic encephalopathy, cerebral edema, coagulopathy, a systemic inflammatory response syndrome, acute renal failure and acute pulmonary failure. The important factors in determining the prognosis of acute liver failure include patients’ age, the severity of encephalopathy and the underlying cause of acute liver failure. The commonly used prognostic indicators to predict mortality in patients with acute liver failure and to identify patients who are likely to benefit from liver transplantation include kings college criteria ( used for liver transplantation ) and model for end-stage liver disease (MELD) score (to predict mortality in patients with chronic and acute liver disease).

Natural History

Acute liver failure is a sudden and severe loss of liver function with evidence of encephalopathy and coagulopathy with elevated prothrombin time (PT) and (INR) in a person without preexisting liver disease. The commonly used time duration for an acute liver disease is < 26 weeks.[1]

Complications

Complications that can develop as a result of acute liver failure are:[2][3][4][5][6][7][8][9][10][11][12]

Prognosis

  • The important factors in determining the prognosis of acute liver failure include patients’ age, the severity of encephalopathy and the underlying cause of acute liver failure.[13][14][15][16][17][18]
  • Several prognostic scoring systems to predict mortality in patients with acute liver failure and to identify patients who are likely to benefit from liver transplantation include:

References

  1. Bower WA, Johns M, Margolis HS, Williams IT, Bell BP (2007). “Population-based surveillance for acute liver failure”. Am J Gastroenterol. 102 (11): 2459–63. doi:10.1111/j.1572-0241.2007.01388.x. PMID 17608778.
  2. Kumar R, Shalimar. Bhatia V, Khanal S, Sreenivas V, Gupta SD; et al. (2010). “Antituberculosis therapy-induced acute liver failure: magnitude, profile, prognosis, and predictors of outcome”. Hepatology. 51 (5): 1665–74. doi:10.1002/hep.23534. PMID 20196116.
  3. Riordan SM, Williams R (1997). “Treatment of hepatic encephalopathy”. N. Engl. J. Med. 337 (7): 473–9. doi:10.1056/NEJM199708143370707. PMID 9250851.
  4. Lee WM (1993). “Acute liver failure”. N. Engl. J. Med. 329 (25): 1862–72. doi:10.1056/NEJM199312163292508. PMID 8305063.
  5. Muñoz SJ (1993). “Difficult management problems in fulminant hepatic failure”. Semin. Liver Dis. 13 (4): 395–413. PMID 8303321.
  6. Hazell AS, Butterworth RF (1999). “Hepatic encephalopathy: An update of pathophysiologic mechanisms”. Proc. Soc. Exp. Biol. Med. 222 (2): 99–112. PMID 10564534.
  7. Larsen FS, Wendon J (2002). “Brain edema in liver failure: basic physiologic principles and management”. Liver Transpl. 8 (11): 983–9. doi:10.1053/jlts.2002.35779. PMID 12424710.
  8. Armstrong IR, Pollok A, Lee A (1993). “Complications of intracranial pressure monitoring in fulminant hepatic failure”. Lancet. 341 (8846): 690–1. PMID 8095592.
  9. Schmidt LE, Larsen FS (2006). “hyperlactatemia“. Crit. Care Med. 34 (2): 337–43. PMID 16424712.
  10. Harry R, Auzinger G, Wendon J (2002). “The clinical importance of adrenal insufficiency in acute hepatic dysfunction”. Hepatology. 36 (2): 395–402. doi:10.1053/jhep.2002.34514. PMID 12143048.
  11. Bihari D, Gimson AE, Waterson M, Williams R (1985). “Tissue hypoxia during fulminant hepatic failure”. Crit. Care Med. 13 (12): 1034–9. PMID 3933911.
  12. Trewby PN, Warren R, Contini S; et al. (1978). “Incidence and pathophysiology of pulmonary edema in fulminant hepatic failure”. Gastroenterology. 74 (5 Pt 1): 859–65. PMID 346431.
  13. Dhiman RK, Seth AK, Jain S, Chawla YK, Dilawari JB (1998). “Prognostic evaluation of early indicators in fulminant hepatic failure by multivariate analysis”. Dig. Dis. Sci. 43 (6): 1311–6. PMID 9635624.
  14. Huo TI, Wu JC, Sheng WY, Chan CY, Hwang SJ, Chen TZ, Lee SD (1996). “Prognostic factor analysis of fulminant and subfulminant hepatic failure in an area endemic for hepatitis B”. J. Gastroenterol. Hepatol. 11 (6): 560–5. PMID 8792311.
  15. Takahashi Y, Kumada H, Shimizu M, Tanikawa K, Kumashiro R, Omata M, Ehata T, Tsuji T, Ukida M, Yasunaga M (1994). “A multicenter study on the prognosis of fulminant viral hepatitis: early prediction for liver transplantation”. Hepatology. 19 (5): 1065–71. PMID 8175127.
  16. Lake JR, Sussman NL (1995). “Determining prognosis in patients with fulminant hepatic failure: when you absolutely, positively have to know the answer”. Hepatology. 21 (3): 879–82. PMID 7875687.
  17. Pauwels A, Mostefa-Kara N, Florent C, Lévy VG (1993). “Emergency liver transplantation for acute liver failure. Evaluation of London and Clichy criteria”. J. Hepatol. 17 (1): 124–7. PMID 8445211.
  18. Rutherford A, King LY, Hynan LS, Vedvyas C, Lin W, Lee WM, Chung RT (2012). “Development of an accurate index for predicting outcomes of patients with acute liver failure”. Gastroenterology. 143 (5): 1237–43. doi:10.1053/j.gastro.2012.07.113. PMC 3480539. PMID 22885329.

Template:WH Template:WS

Diagnosis

Diagnosis

Diagnostic Study of Choice | History and Symptoms | Physical Examination | Laboratory Findings | X Ray | CT | Ultrasound | Other Imaging Findings | Other Diagnostic Studies

Treatment

Treatment

Medical Therapy | Surgery | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies

Case Studies

Case Studies

Case #1

Template:WH Template:WS

Looking for the patient version?

Back to the patient-friendly article

© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH